Advertisement

Relacorilant Plus Nab-paclitaxel for Ovarian Cancer
Posted: 07/12/2023 | By: Chase Doyle

In a report published by Colombo et al in the Journal of Clinical Oncology, investigators examined the combination of the selective glucocorticoid receptor modulator relacorilant plus nab-paclitaxel in pretreated patients with recurrent ovarian cancer.

Question 1 of 5

How does endogenous cortisol contribute to tumor progression?

Choose 1

A
It directly increases the size of the tumor
B
It decreases the body’s immune response to the tumor
C
It promotes tumor progression through suppression of the apoptotic pathways used by cytotoxic agents
D
It has no significant effect on tumor progression

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage